Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 16855
Country/Region: Nigeria
Year: 2016
Main Partner: Centre for Integrated Health Programs
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $21,567,887 Additional Pipeline Funding: $2,112,586

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $7,619,358
Care: Orphans and Vulnerable Children (HKID) $3,548,763
Care: TB/HIV (HVTB) $647,948
Care: Pediatric Care and Support (PDCS) $732,209
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $30,000
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Testing: HIV Testing and Counseling (HVCT) $3,946
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,330,904
Treatment: Adult Treatment (HTXS) $7,029,776
Treatment: Pediatric Treatment (PDTX) $624,983
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 993
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 325
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 1,102
GEND_GBV Number of people receiving post-GBV care 2017 1,427
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 32,583
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 29,239
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 482,179
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 282,642
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 826,643
HTS_TST Service Delivery Point (Community): Homebased testing 2017 23,905
HTS_TST Service Delivery Point (Community): Index testing 2017 4,194
HTS_TST Service Delivery Point (Community): Mobile testing 2017 7,968
HTS_TST Service Delivery Point (Community): Other 2017 5,890
HTS_TST Service Delivery Point (Facility): Index testing 2017 1,340
HTS_TST Service Delivery Point (Facility): Inpatient 2017 1,321
HTS_TST Service Delivery Point (Facility): Malnutrition facilities 2017 842
HTS_TST Service Delivery Point (Facility): Other PITC 2017 60
HTS_TST Service Delivery Point (Facility): Outpatient 2017 393,849
HTS_TST Service Delivery Point (Facility): Pediatric 2017 61,496
HTS_TST Service Delivery Point (Facility): PMTCT 2017 163,140
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 16,098
HTS_TST Service Delivery Point (Facility): VCT 2017 146,540
HTS_TST Sum of Aggregated Age/Sex <15 2017 61,822
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 764,821
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 826,643
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 1,207
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 969
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 13,857
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 10,505
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 60
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 67
LAB_PT CD4: Number of laboratories that perform this testing 2017 67
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 1
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 70
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 78
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 78
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 1
OVC_SERV Age/Sex: 18+ Female 2017 37,718
OVC_SERV Age/Sex: 18+ Male 2017 4,186
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 37,723
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 4,193
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 83,820
OVC_SERV Sum of Age/Sex disaggregates 2017 41,904
PMTCT_ART Already on ART at beginning of current pregnancy 2017 1,853
PMTCT_ART New on ART 2017 2,402
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 163,154
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 3,186
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 1,069
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 14
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 45
PMTCT_EID Sum of Infant Age disaggregates 2017 4,255
PMTCT_STAT By: Known positives at entry 2017 2,345
PMTCT_STAT By: Number of new positives identified 2017 2,135
PMTCT_STAT Number of new ANC and L&D clients 2017 171,740
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 163,154
PMTCT_STAT Sum of Positives Status disaggregates 2017 4,480
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 24
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 509
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 24
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 509
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 1,185
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 1,066
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 4,319
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 3,873
TB_SCREENDX Screen Result: Screened Positive for TB 2017 4,789
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 142,824
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 54,740
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 5,607
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 5,858
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 209,029
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 110
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,736
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 127
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 3,263
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 6,170
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 6,851
TX_CURR Aggregated Age/Sex: <15 Female 2017 4,564
TX_CURR Aggregated Age/Sex: <15 Male 2017 4,859
TX_CURR Aggregated Age/Sex: 15+ Female 2017 88,150
TX_CURR Aggregated Age/Sex: 15+ Male 2017 32,827
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 130,400
TX_CURR Sum of Aggregated Age/Sex <15 2017 9,423
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 120,977
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 130,400
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 777
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 686
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 11,956
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 10,592
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 24,011
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 24,011
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 130,754
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 117,681
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 3,273
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 3,400
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 80,897
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 30,111
TX_PVLS Numerator: Indication: Routine 2017 94,151
TX_PVLS Numerator: Indication: Targeted 2017 23,530
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 3,657
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 3,775
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 89,884
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 33,438
TX_PVLS_den Denominator: Indication: Routine 2017 104,192
TX_PVLS_den Denominator: Indication: Targeted 2017 26,562
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 699
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 715
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 17,071
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,080
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 24,565
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 28,884
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 808
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 851
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 20,058
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 7,167
Cross Cutting Budget Categories and Known Amounts Total: $1,891,727
Human Resources for Health $431,100
Food and Nutrition: Commodities $59,743
Economic Strengthening $128,406
Education $62,453
Water $97,650
Renovation $272,365
Gender: Gender Based Violence (GBV) $760,432
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Motor Vehicles: Purchased $79,578